Health Care - Pharmaceuticals/Major: 2011 First

Timothy Anderson takes the prize for a third straight year. The Sanford C. Bernstein & Co. analyst, who works out of San Francisco, “has an impressive network of industry contacts that

Timothy Anderson Sanford C. Bernstein & Co. The buy side says: “Tim offers a long-term view on a sector that is crowded with short-term thinkers.”

Timothy Anderson takes the prize for a third straight year. The Sanford C. Bernstein & Co. analyst, who works out of San Francisco, “has an impressive network of industry contacts that keep him informed of every development,” marvels one buy-side backer. Anderson, 43, upgraded Pfizer from neutral to outperform last November, at $16.90; he believed the market was too preoccupied with the November 2011 expiration of the New York–based company’s patent on its best-selling cholesterol drug, Lipitor, and not focused enough on the new products in Pfizer’s pipeline. Anderson highlighted the call in March, in a report informing clients that the company was thinking of divesting itself of multiple divisions so that it could concentrate exclusively on pharmaceuticals research. By the end of August, the stock had advanced 12.3 percent since the analyst’s upgrade, to $18.98; during the same period the sector climbed just 3.3 percent.

Related